Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is clinical trial results in Alzheimer disease!
|Slideshows|November 22, 2016
AHA 2016: Cardiovascular Health and Cognition
Author(s)Samantha J. Peterson
Do lipid-lowering medications or low vitamin D levels in mid-life cause neurocognitive deficits? What effect does hypotension have on TBI outcomes?
Advertisement
Presentations at the American Heart Association Scientific Sessions examined the association of PCSK9 inhibitors and neurocognitive deficits, the effect of depth and dose of hypotension on mortality in traumatic brain injury, and a possible link between low vitamin D levels in mid-life and cognitive deficits 20 years later.
Advertisement
Related to this article
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
A. Blake Buletko, MD, and Galina Gheihman, MD, discuss their career paths in neurology, the role of mentorship and resilience, and strategies for navigating professional growth as early-career clinician-educators.
One-year KYSA-6 data showed KYV-101, a CD19 CAR T-cell therapy, produced durable, drug-free responses in generalized myasthenia gravis.
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
The FDA has granted Scholar Rock's apitegromab fast track designation for the treatment of patients with living facioscapulohumeral muscular dystrophy as the company's phase 2 FORGE study dosing begins.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
What's Next in Ataxia: Pipeline Overview of Investigational Therapeutics
2
FDA Grants Fast Track Designation to Apitegromab for Facioscapulohumeral Muscular Dystrophy
3
Ulefnersen Meets Primary End Point in Phase 3 FUSION Trial for FUS-ALS
4
Azetukalner NDA Submitted, EMA Gives Approval Recommendation to Ocrelizumab, Phase 3 FUSION Trial Meets End Points
5